Ariceum International AG is the Swiss affiliate of Ariceum Therapeutics GmbH, a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of hard-to-treat cancers. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan.
Products, services, technology
SSO110, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) in clinical development stage in neuroendocrine tumours.
